3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Carcinoma, Hepatocellular
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Carcinoma, Renal Cell
7
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Differentiated Thyroid Cancer (DTC)
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Advanced Malignancies
1
Advanced Endometrial Cancer
1
Interventions
Olanzapine
4
Cyclophosphamide
4
Voriconazole
3
Tranexamic Acid
3
Standard of Care
3
nilotinib
2
letermovir
2
fludarabine phosphate
2
Zoledronic Acid
2
Whole-Body Irradiation
2
Practice Guidelines as Topic
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methods
2
Imatinib Mesylate
2
Educational Status
2
Early Intervention, Educational
2
Doxorubicin
2
Cyclosporins
2
Cyclosporine
2
venetoclax
1
trihexyltetradecylphosphonium chloride
1
thymoglobulin
1
shengxuening
1
posaconazole
1
pembrolizumab
1
olaparib
1
maribavir
1
lenvatinib
1
ferrous succinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hematologic Neoplasms
×
lenvatinib
×
Clear all
NCT03486873
2026-05-26
MK-3475-587
Merck Sharp & Dohme LLC
Phase 3
Recruiting
3,500 enrolled